NexGel

NXGL

Market cap $19.4M

Overview Fund Activity

2.41 USD

-0.06

2.43%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

2.47

+0.06

2.49%

1 day

-2.43%

5 days

4.78%

1 month

-11.07%

3 months

9.05%

6 months

-20.2%

Year to date

-37.08%

1 year

-11.72%

5 years

-31.53%

10 years

-31.53%

About: NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.

Employees: 19

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

0.29% less ownership

Funds ownership: 9.65% [Q1] → 9.36% (-0.29%) [Q2]

5% less capital invested

Capital invested by funds: $1.95M [Q1] → $1.85M (-$103K) [Q2]

6% less funds holding

Funds holding: 16 [Q1] → 15 (-1) [Q2]

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

See Fund Rankings

Financial journalist opinion

NEXGEL, Inc. (NXGL) Q2 2025 Earnings Call Transcript

NEXGEL, Inc. (NASDAQ:NXGL ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adam R. Levy - CEO, President & Director Joseph F.

NEXGEL, Inc. (NXGL) Q2 2025 Earnings Call Transcript

NEXGEL to Report Second Quarter 2025 Financial Results on August 12th

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.

NEXGEL to Report Second Quarter 2025 Financial Results on August 12th

NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement

LANGHORNE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 413,044 shares of its common stock (the “Shares”) at $2.30 a share. In a concurrent private placement, NEXGEL also agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to an aggregate of 206,522 shares of common stock (the “Unregistered Warrants”). The Unregistered Warrants will have an exercise price of $4.25 per share and are exercisable immediately upon issuance with a term of five years from the date of issuance.

NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement

NEXGEL and STADA AG Announce Expansion of Partnership for North America

LANGHORNE, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced expanding its partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health. The expansion includes the planned launch of digestive enzyme formulas and solutions targeting scars and stretch marks.

NEXGEL and STADA AG Announce Expansion of Partnership for North America

NEXGEL, Inc. (NXGL) Q1 2025 Earnings Call Transcript

NEXGEL, Inc. (NASDAQ:NXGL ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer Joe McGuire - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Eric Ramos - Titan Capital Management Operator Good afternoon. I will be your conference operator today.

NEXGEL, Inc. (NXGL) Q1 2025 Earnings Call Transcript

NEXGEL to Report First Quarter 2025 Financial Results on May 13th

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.

NEXGEL to Report First Quarter 2025 Financial Results on May 13th

NEXGEL, Inc. (NXGL) Q4 2024 Earnings Call Transcript

NEXGEL, Inc. (NASDAQ:NXGL ) Q4 2024 Earnings Conference Call March 24, 2025 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer Joe McGuire - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Good afternoon. I will be your conference operator today.

NEXGEL, Inc. (NXGL) Q4 2024 Earnings Call Transcript

NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results

Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year

NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results

NEXGEL to Report Fourth Quarter and Full Year 2024 Financial Results on March 24th

Management will host a conference call at 4:30 p.m. ET on the same day LANGHORNE, Pa.

NEXGEL to Report Fourth Quarter and Full Year 2024 Financial Results on March 24th

NEXGEL to Participate in Webull Consumer Virtual Webinar on February 18, 2025

LANGHORNE, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the Webull Consumer Virtual Webinar on February 18, 2025.

NEXGEL to Participate in Webull Consumer Virtual Webinar on February 18, 2025

See News Rankings

Charts implemented using Lightweight Charts™